Nav: Home

DNA sequencing determines lymphoma origin, prognosis, Stanford researchers say

November 09, 2016

Sequencing tiny bits of DNA circulating in the blood of patients with lymphoma can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance, according to researchers at the Stanford University School of Medicine.

This knowledge could help personalize cancer treatment by revealing which patients are likely to be treated successfully and those who may have a poorer prognosis.

Tracking sequence changes over time could also provide a kind of early warning system to identify the emergence of an aggressive form of the cancer by providing a real-time window into tumor evolution. The findings bolster the growing notion that noninvasive, blood-based biopsies of what's known as circulating tumor DNA are likely to transform cancer care.

"Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said assistant professor of medicine Ash Alizadeh, MD, PhD. "We've moved beyond just measuring disease burden based on the amount of tumor DNA in the blood."

Alizadeh and assistant professor of radiation oncology Maximilian Diehn, MD, PhD, share senior authorship of the study, which will be published Nov. 9 in Science Translational Medicine. Postdoctoral scholars Florian Scherer, MD, and David Kurtz, MD, and instructor Aaron Newman, PhD, are the lead authors.

Longitudinal study of 92 patients

The researchers conducted a study of 92 prospectively enrolled patients with diffuse large B-cell lymphoma. DLBCL is the most common type of non-Hodgkin lymphoma and is highly biologically variable. As a result, patients vary widely in their response to treatment. About one-third of seemingly successfully treated patients eventually relapse, or their tumors become resistant to treatment. Additionally, a form of indolent B cell lymphoma, which progresses slowly with only mild symptoms, can transform without warning into an aggressive form of the disease.

"This transformation is very difficult to detect, and usually requires an invasive biopsy to diagnose," said Diehn. "Our approach will allow us to monitor patients over time with a simple blood test, and may help us identify transformation much earlier."

The researchers used an enhanced version of a technique they developed called CAPP-Seq to isolate and sequence circulating tumor DNA, or ctDNA, from blood samples from the patients. Unlike previous studies, which tracked lymphoma progression by monitoring the sequence of just one cancer-associated protein, CAPP-Seq can identify a much larger range of mutations in the tumor genome.

They then compared the ctDNA sequences obtained from the patients' stored blood samples with those of the tumor cells from invasive biopsies, and paired the information with what was known about the course of the patient's disease and eventual outcome. They found that low levels of ctDNA after diagnosis but before treatment correlated strongly with progression-free survival in the patients. Those with higher levels of ctDNA faired more poorly overall. Furthermore, they were able to detect the presence of ctDNA in the blood of relapsing patients on average six months before any clinical symptoms appeared and as long as 2.5 years before clinical signs of relapse.

Determining cancer's cell of origin

Perhaps even more importantly, however, the researchers found they could use CAPP-Seq to determine the type of B cell from which the cancer originated and predict prognosis. About two-thirds of people with the germinal center subtype live for five years or more after diagnosis, while those with activated B-cell-like tumors have a poorer prognosis with current treatment regimes. These subtypes are known to predict differential responses to emerging targeted therapies, but they are cumbersome to measure accurately and require biopsies.

Finally, the researchers were able to predict from the ctDNA sequences those patients whose disease was transforming into a much more aggressive form prior to the emergence of clinical symptoms, and even to identify and track specific mutations known to inhibit the response to the targeted therapy with a drug known as ibrutinib.

"In this study we've shown five distinct ways -- by quantifying tumor burden, identifying disease subtype, cataloging mutations, predicting transformation and providing early warnings of recurrence -- that circulating tumor DNA can yield potentially clinically useful information," said Diehn. "Now we're eager to conduct prospective studies in recently diagnosed patients to learn how we can best improve patient care."

Alizadeh and Diehn are both investigators at the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford.

The team's work is an example of Stanford Medicine's focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
-end-
Other Stanford co-authors of the study are research associates Henning Stehr, PhD, and Chih Long Liu, PhD; former research assistant Alexander Craig; postdoctoral scholars Mohammad Esfahani, PhD, and Daniel Klass, PhD; former postdoctoral scholar Alexander Lovejoy, PhD; graduate student Jacob Chabon; research assistant Li Zhou; clinical trials assistant Cynthia Glover; assistant professor of surgery Brendan Visser, MD; associate professor of surgery George Poultsides, MD; professor of medicine Ranjana Advani, MD; clinical assistant professor of medicine Lauren Maeda, MD; clinical assistant professor of medicine Neel Gupta, MD; professor of medicine Ronald Levy, MD; assistant professor of pathology Robert Ohgami, MD, PhD; and clinical assistant professor of pathology Christian Kunder, MD, PhD.

Newman, Klass and Alizadeh are co-inventors on patent applications related to CAPP-Seq, and Newman, Diehn and Alizadeh are consultants for Roche Molecular Systems. Lovejoy and Klass are currently employed by Roche Molecular Systems.

The research was supported by the Damon Runyon Cancer Research Foundation, the American Society of Hematology, the V Foundation for Cancer Research, the German Research Foundation, the Stanford TRAM Pilot Grant, the American Society of Clinical Oncology and the National Institutes of Health (grants K99CA187192, R01CA188298, and 1DP2CA186569).

Stanford's departments of Medicine and of Radiation Oncology also supported the work.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Lucile Packard Children's Hospital Stanford. For information about all three, please visit http://med.stanford.edu.

Stanford University Medical Center

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.